The nasal polyposis drugs market is expected to nearly double by 2033, growing at a CAGR of approximately 6.7%. Growth is led by corticosteroids (≈55% share) and rising adoption of monoclonal biologics targeting IL‑5 and IgE pathways in chronic rhinosinusitis with nasal polyps https://www.datamintelligence.com/research-report/nasal-polyposis-drugs-market